Urology Times staff

"The most important thing that I think came out of this study is really the BMI inflection point for complications. We saw an abrupt rise in complications around a BMI of 40," says Cassandra K. Kisby, MD, MS.

In this interview, Robert Reiter, MD, MBA, discusses the accuracy of PSMA-PET scans, false negative and false positive rates, and how treatment with ADT affects PSMA uptake.

“We don't have the sex therapists or psychologists who specialize in sexual dysfunction here... It's incredibly important, because if it doesn't start out as psychological, certainly, it becomes psychological, at least in some measure,” says Thomas M. Jaffe, MD.

"I would say that the biggest take-home is that many of our patients are using social media for their health care information, and this may influence their preferences [and] their decision-making," says Alexandra Tabakin, MD.

In this interview, Mark D. Tyson, MD, MPH, discusses TAR-200 and other novel investigational treatments for non–muscle-invasive bladder cancer.

"The learning curve is fairly quick; you can pick this up pretty easily vs some of the other prostate procedures that can take a little bit more time to learn how to use," says Matthew E. Sterling, MD.

"in general, we can use a simpler regimen [of testosterone replacement therapy] and achieve normal levels," says Peter N. Tsambarlis, MD.

“What we found was that the rate of complications due to infection were 2.6% with the transrectal approach, and 2.7% with the transperineal,” says Badar M. Mian, MD.

"There are situations where you can use a biparametric or noncontrast approach; most of them you will prefer still to use an approach with contrast," says Leonardo Kayat Bittencourt, MD, PhD.

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

“With 2 years of follow-up, we saw that there was no difference in these 2 groups in terms of overall survival, metastasis-free survival, or recurrence-free survival,” says Saum B. Ghodoussipour, MD.

"You could look at a person and say that they're extraordinarily successful...but they can be completely miserable," says Anne M. Suskind, MD, MS, FACS, FPMRS.

"Probably the most surprising finding was actually that there were several videos created by health care professionals that contain misinformation," says Alexandra Tabakin, MD.

“We’re in a very exciting time for those of us who take care of patients with bladder cancer. There are a lot of new emerging treatment options,” says Vikram M. Narayan, MD.

“In this study, we sought to compare our early outcomes with transperineal prostate biopsy compared to transrectal,” says Saum B. Ghodoussipour, MD.

"We had interest in trying to look at mechanisms and seeing if the obvious question is, well, if obesity is associated with progressing cancer, can we disrupt that link if we help men lose weight in a healthy way," says Jill Hamilton Reeves, PhD, RD, CSO.

"The limitation of [TURP] is you're shaving out prostate tissue in a layer at a time, and you stop when you think you're deep enough, whereas with an Aquablation, you map all that out ahead of time," says Brian Friel, MD.

“It seems that DRE does not add a clinically or statistically significant [benefit] to PSA testing alone in detecting prostate cancer,” says Shahrokh F. Shariat, MD.

"We have information today from a number of well-powered, well-designed prospective studies showing that performing an MRI before the decision to do the first biopsy adds value," says Leonardo Kayat Bittencourt, MD, PhD.

“Our hope is to really change the practice of medicine,” says Jim C. Hu, MD, MPH.

Daniel Spratt, MD, highlights the evolving paradigm of PET-based imaging agents in prostate cancer, with a focus on the impact of PSMA-PET imaging.

"Overall, our conclusion is we observed more benefit in apalutamide vs abiraterone," says Mehmet Asim Bilen, MD.

"I think these results particularly apply to practicing urologists that have the opportunity to train residents," says Kathryn Marchetti, MD.

“The patients with CDK12, the combination had a PSA50 of about 83% compared to the ABI/placebo of about only 62%,” says Neal D. Shore, MD.

"We have over 30 years of safety data, and no adverse events in over 30 years," says Heather Florio.

"We identified that in our site, we were ordering almost 1600 cystoscopy packs. A lot of the materials that were in those packages were unnecessary for an outpatient procedure," says Malissa Williams.

“We wanted to do a modeling analysis using patient-level data to see if we can estimate whether or not there is a long-term cure or overall survival benefit for these patients,” says Daniel M. Geynisman, MD.

“My goal was very simple. Five years from now, there will be X number of more fathers, brothers, grandfathers who will be having dinners with their families because of what I'm doing, because I will find the cancer early and hopefully make an impact,” says Ashutosh Tewari, MD.

"Overall, our conclusion is, in this real-world analyses, more patients treated with apalutamide survive by 24 months following treatment initiation compared to enzalutamide," says Mehmet Asim Bilen, MD.